Globus Medical Inc (GMED) |
63.38 -1.06 (-1.64%)
|
01-27 06:04 |
Open: |
64.56 |
Pre. Close: |
64.44 |
High:
|
65 |
Low:
|
63.3 |
Volume:
|
209,436 |
Market Cap:
|
6,254M |
|
|
Globus Medical, Inc., a medical device company, focuses on the development and commercialization of implants that heal patients with musculoskeletal disorders. Its spine product portfolio includes a range of implant and surgical approach options that can be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and regenerative biologic products, such as allografts and synthetic alternatives that are adjunctive treatments used in combination with stabilizing implant hardware. In addition, it provides motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous distraction devices, and interventional pain management solutions to treat vertebral compression fractures; imaging, navigation, and robotic assisted surgery technology solutions; and hip and knee joint solutions, as well as distributes human cell, tissue, and cellular and tissue based products. Further, the company offers expandable spacer products, which include RISE, RISE-L, CALIBER, CALIBER-L, ALTERA, ELSA, ELSA-ATP, SABLE, MAGNIFY, MAGNIFY-S, FORTIFY, and XPand; CREO thoracolumbar stabilization platform that offers instruments and implants for treating pathologies; CREO MIS and CREO MCS, options designed for less invasive surgery and minimal muscle disruption; CREO Derotation and CREO Rod Link Reducer systems, which help to streamline various derotation maneuvers for deformity correction; CREO Addition that provides a range of connectors; and CREO Fenestrated, a cement augmented pedicle screw system for patients with advanced stage tumors and limited life expectancy, as well as QUARTEX, an occipito-cervico-thoracic stabilization system. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania. |
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
65.138 - 65.53 |
65.53 - 65.821 |
Low:
|
62.369 - 62.886 |
62.886 - 63.27 |
Close:
|
62.706 - 63.464 |
63.464 - 64.026 |
|
Technical analysis |
as of: 2021-01-26 4:44:30 PM |
Overall:
|
|
Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
Target: |
Six months: 76.59 One year: 79.66 |
Support: |
Support1: 61.33 Support2: 51.03 |
Resistance: |
Resistance1: 65.58 Resistance2: 68.20 |
Pivot: |
65.42  |
Moving Average: |
MA(5): 64.86 MA(20): 65.26 
MA(100): 57.78 MA(250): 52.36  |
MACD: |
MACD(12,26): 0.52 Signal(9): 0.98  |
Stochastic oscillator: |
%K(14,3): 29.02 %D(3): 42.69  |
RSI: |
RSI(14): 45.86  |
52-week: |
High: 68.20 Low: 33.41 Change(%): 19.3 |
Average Vol(K): |
3-Month: 59041 10-Days: 39525 |
|
Price, moving averages and Bollinger Bands |
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.GMED has closed above bottom band by 8.9%. Bollinger Bands are 25.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
Headline News |
Wed, 20 Jan 2021 Globus Medical Inc. Class A (GMED) Soars 2.51% on January 20 - Equities.com
Tue, 19 Jan 2021 Globus Medical (GMED) US Spine Grows, Pricing Pressure Stays - Yahoo Finance
Mon, 11 Jan 2021 FY2020 EPS Estimates for Globus Medical, Inc. Raised by Analyst (NYSE:GMED) - MarketBeat
Fri, 08 Jan 2021 Globus Medical Inc. Class A (GMED) Soars 1.14% on January 08 - Equities.com
Fri, 08 Jan 2021 Credit Suisse Group Raises Globus Medical (NYSE:GMED) Price Target to $75.00 - MarketBeat
Fri, 01 Jan 2021 $234.25 Million in Sales Expected for Globus Medical, Inc. (NYSE:GMED) This Quarter - MarketBeat
|
Financial Analysis |
Growth |
n/a |
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
Profitability |
n/a |
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
Solvency |
 |
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
Efficiency |
n/a |
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NYSE |
Sector: Healthcare |
Industry: Medical Devices |
Shares Out. (M) |
76 |
Shares Float (M) |
75 |
% Held by Insiders
|
0.88 |
% Held by Institutions
|
68.39 |
Shares Short (K)
|
1,400 |
Shares Short P. Month (K)
|
1,990 |
Stock Financials |
EPS
|
0.930 |
EPS Est This Year
|
1.270 |
EPS Est Next Year
|
1.390 |
Book Value (p.s.)
|
14.360 |
Profit Margin
|
12.36 |
Operating Margin
|
13.92 |
Return on Assets (ttm)
|
4.5 |
Return on Equity (ttm)
|
6.9 |
Qtrly Rev. Growth
|
10.1 |
Gross Profit (p.s.)
|
7.941 |
Sales Per Share
|
10.064 |
EBITDA (p.s.)
|
2.188 |
Qtrly Earnings Growth
|
15.40 |
Operating Cash Flow (M)
|
173 |
Levered Free Cash Flow (M)
|
51 |
Stock Valuations |
PE Ratio
|
68.15 |
PEG Ratio
|
3.47 |
Price to Book value
|
4.41 |
Price to Sales
|
6.30 |
Price to Cash Flow
|
27.94 |
Stock Dividends |
Dividend
|
|
Forward Dividend
|
|
Dividend Yield
|
|
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
7 Binary Options
|
Your Ad Here
|
|